Identification of functional enhancer variants associated with type I diabetes in CD4+ T cells

Front Immunol. 2024 Jun 14:15:1387253. doi: 10.3389/fimmu.2024.1387253. eCollection 2024.

Abstract

Type I diabetes is an autoimmune disease mediated by T-cell destruction of β cells in pancreatic islets. Currently, there is no known cure, and treatment consists of daily insulin injections. Genome-wide association studies and twin studies have indicated a strong genetic heritability for type I diabetes and implicated several genes. As most strongly associated variants are noncoding, there is still a lack of identification of functional and, therefore, likely causal variants. Given that many of these genetic variants reside in enhancer elements, we have tested 121 CD4+ T-cell enhancer variants associated with T1D. We found four to be functional through massively parallel reporter assays. Three of the enhancer variants weaken activity, while the fourth strengthens activity. We link these to their cognate genes using 3D genome architecture or eQTL data and validate them using CRISPR editing. Validated target genes include CLEC16A and SOCS1. While these genes have been previously implicated in type 1 diabetes and other autoimmune diseases, we show that enhancers controlling their expression harbor functional variants. These variants, therefore, may act as causal type 1 diabetic variants.

Keywords: 3D genome architecture; GWAS; enhancer elements; massively parallel reporter assay (MPRA); non-coding variants; type 1 diabetes.

MeSH terms

  • CD4-Positive T-Lymphocytes* / immunology
  • CD4-Positive T-Lymphocytes* / metabolism
  • Diabetes Mellitus, Type 1* / genetics
  • Diabetes Mellitus, Type 1* / immunology
  • Enhancer Elements, Genetic* / genetics
  • Genetic Predisposition to Disease*
  • Genetic Variation
  • Genome-Wide Association Study
  • Humans
  • Lectins, C-Type / genetics
  • Polymorphism, Single Nucleotide
  • Quantitative Trait Loci
  • Suppressor of Cytokine Signaling 1 Protein / genetics

Substances

  • Suppressor of Cytokine Signaling 1 Protein
  • SOCS1 protein, human
  • Lectins, C-Type

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK103667).